A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Completed · Phase 1

Conditions studied: Diabetic Macular Edema

In brief

A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.

Key facts

Study ID

NCT02103283

Run by

Amgen

People needed

5

Starts

2014-10-01

Expected to finish

2016-08-01

Last updated by the study team

2025-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of diabetes mellitus with Hemoglobin A1c <8.5%
• IGF 1 in serum > 106 ng/mL
• Women of child-bearing potential must have negative pregnancy test and be willing and able to use two different methods of contraception, one of which must be oral contraceptive or depot formulation. Males must be surgically sterile or agree to use barrier contraception
• Clinically significant DME of less than 12 months duration
• Non-proliferative diabetic retinopathy of moderate severity
• Best corrected electronic ETDRS letter score < 78 and > 24

You may not qualify if…

• Unstable-uncontrolled diabetes as demonstrated by a change in diabetes medication greater than 15% in the previous 60 days.
• Significant renal disease, myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure
• Blood pressure > 180/110
• Anti-vascular endothelial growth factor (VEGF) treatment within two months prior to enrollment
• History of pan retinal photocoagulation within four months prior to enrollment
• History of ocular surgery within four months prior to enrollment
• History of systemic treatment with corticosteroids within 3 months prior to enrollment

Where it is running

• David S Boyer — Beverly Hills, California, United States
• David A Eichenbaum, MD — St. Petersburg, Florida, United States
• Diana Do, MD — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.